NCT06907615View on ClinicalTrials.gov

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

243

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

April 20, 2028

Study Completion Date

June 4, 2028

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

HLX43 DOSE 1 (2.0 mg/kg)

Dose 1; 2.0 mg/kg; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

DRUG

HLX43 DOSE 2 (2.5 mg/kg)

Dose 2; 2.5 mg/kg; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Trial Locations (2)

77030

NOT_YET_RECRUITING

MD Anderson Cancer Hospital, Houston

100021

RECRUITING

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
collaborator

Henlius USA Inc.

UNKNOWN

lead

Shanghai Henlius Biotech

INDUSTRY

NCT06907615 - A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter